# Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia

> **NCT06832371** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)** · enrollment: 73 (actual)

## Conditions studied

- Homozygous Familial Hypercholesterolemia (HoFH)
- Major Adverse Cardiovascular Events (MACE)
- Dyslipidemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06832371
- **Lead sponsor:** Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-09-09
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 73 (ACTUAL)
- **Last updated:** 2026-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832371, "Evaluation of the Effect of Lomitapide Treatment on Major Adverse Cardiovascular Events (MACE) in Patients With Homozygous Familial Hypercholesterolemia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06832371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*